Powering advanced, more human-relevant in vitro disease models
Our partner Axol Bioscience is the first choice for high-quality, functionally relevant human iPSC-derived cells.
As drug discovery continues to explore more human-relevant approaches to disease modeling, human induced pluripotent stem cell (iPSC) technology is gaining momentum. Using this technology, consented blood or skin donations from patients and healthy donors are ‘reprogrammed’ into a stem cell state, from which they can be turned into any cell type including neurons, neuroinflammatory cells, muscle cells and cardiac cells.
iPSC-derived cells can then be grown on their own in monocultures or in co-cultures of different cell types to make advanced in vitro models for research, toxicity studies and drug discovery. These models can be used to test compounds for safety and effectiveness.
High-quality iPSC-derived cells can be used to fuel robust, scalable in vitro human disease models to accelerate and de-risk drug discovery.
At Axol Bioscience, they've spent the past decade developing the manufacturing capabilities to produce high-quality, functional iPSC-derived cells, axoCells, with excellent consistency. Your research can benefit from the quality-focused approach, with a catalog of robust, highly relevant iPSC-derived neurons and cardiomyocytes developed at their ISO 9001:2015-accredited production facility.